For patients with moderate-to-severe atopic dermatitis (AD), the FDA approved two oral JAK1 inhibitors in January: abrocitinib (Cibinqo®) and upadacitinib (Rinvoq™). These are the first oral JAK inhibitors available for AD in the U.S.
Read more about their efficacies at the American Academy of Dermatology.